Seven Fleet Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Seven Fleet Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.12M	Buy	+403,545	New	+$2.74M	0.51%	34

Other funds holding SGMT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Seven Fleet Capital Management's SGMT Position: Q2 2026 in Review

Seven Fleet Capital Management opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 403,545 shares worth $3.12M. The stake represents 0.51% of the portfolio and ranks #34 among its holdings.

122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

Seven Fleet Capital Management held 403,545 shares of Sagimet Biosciences worth $3.12M as of Q2 2026.
Sagimet Biosciences was a new Seven Fleet Capital Management position in Q2 2026.
Sagimet Biosciences made up 0.51% of Seven Fleet Capital Management's portfolio in Q2 2026, its #34 holding.
122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.